Under an R&D partnership Beckley Psytech, dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, will jointly fund continuing development of Lophora ApS’ pipeline of proprietary NCEs for treatment-resistant depression, and other potential indications such as anxiety, post-traumatic stress disorder and substance abuse. Click to read more.
Beckley Psytech bolsters pipeline of next-generation psychedelic medicines with research collaboration and strengthening of relationship with Lophora ApS Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s) Broad collaboration with Lophora will further strengthen Beckle.
Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding